Skip to main content
Eurobio Scientific logo

Eurobio Scientific — Investor Relations & Filings

Ticker · ALERS ISIN · FR0013240934 LEI · 969500IQEUEH806GE257 PA Manufacturing
Open in API
Filings indexed 198 across all filing types
Latest filing 2020-07-15 M&A Activity
Country FR France
Listing PA ALERS

About Eurobio Scientific

https://www.eurobio-scientific.com

Eurobio Scientific is an integrated company specializing in in vitro diagnostics (IVD). Its activities cover the entire value chain, from research and development to the manufacturing and commercialization of specialty diagnostic products. The company's core focus areas are transplantation, oncology, and infectious diseases. In transplantation, it provides reagents, software for transplant matching and chimerism monitoring, and culture media for cornea grafts. For oncology, it develops and manufactures prognostic genomic tests for breast and prostate cancer. The group also markets a comprehensive portfolio of molecular tests for detecting infectious diseases, alongside solutions for immunology, fertility, and dermatological conditions.

Recent filings

Filing Released Lang Actions
Eurobio Scientific expands into Switzerland, Germany, Austria and Benelux by acquiring the diagnostic company TECOmedical AG
M&A Activity Classification · 99% confidence The document is a press release dated July 15, 2020, announcing the acquisition of TECOmedical AG by Eurobio Scientific. It details the strategic rationale, the acquired company's profile, and includes quotes from management. This type of announcement, concerning corporate development, M&A activity, and strategic positioning, fits best under the Merger & Acquisition (TAR) category, as it is a direct announcement of a takeover/acquisition proposal being executed. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a general regulatory announcement (RNS), but a specific corporate action announcement.
2020-07-15 English
EUROBIO SCIENTIFIC : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE CONTRACTE PAR EUROBIO SCIENTIFIC AVEC LOUIS CAPITAL MARKETS
Capital/Financing Update Classification · 99% confidence The document is titled "BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE CONTRACTE PAR EUROBIO SCIENTIFIC AVEC LOUIS CAPITAL MARKETS" (Semi-annual balance sheet of the liquidity contract...). It explicitly reports the status of a liquidity contract (market making agreement) as of June 30, 2020, comparing it to the previous semi-annual balance (December 31, 2019), and details trading activity for the first half of 2020. This type of periodic report detailing the status of a specific financial arrangement, often related to share trading/market stability, does not fit neatly into the primary financial report categories (10-K, IR, ER). It is a specific regulatory or contractual disclosure. Given the options, it is a specialized financial disclosure. Since it is a detailed, periodic report on a specific financial mechanism (liquidity contract), and not a general earnings release (ER) or comprehensive interim report (IR), it best fits the general 'Regulatory Filings' (RNS) category as a specific, non-standard disclosure, or potentially a specialized 'Capital/Financing Update' (CAP) if the liquidity contract is viewed as a financing tool, but RNS is a safer fallback for specific contractual updates. However, since it is a detailed report on the status of a contract, and not just an announcement of a report, it is not RPA. It is a periodic report on a specific financial arrangement. Given the options, 'RNS' (Regulatory Filings/Miscellaneous) is the most appropriate catch-all for this specific contractual balance sheet update.
2020-07-08 French
EUROBIO SCIENTIFIC : Compte-rendu de l’assemblée générale ordinaire et extraordinaire annuelle
AGM Information Classification · 99% confidence The document is titled "Compte-rendu de l'assemblée générale ordinaire et extraordinaire annuelle d'Eurobio Scientific" (Minutes/Report of the Annual Ordinary and Extraordinary General Meeting of Eurobio Scientific). It explicitly states that the general meeting was held, quorum was achieved, and details the resolutions adopted, such as the approval of 2019 annual accounts and authorizations for share buybacks and capital increases. This content directly relates to the proceedings and outcomes of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R). The document length (3393 chars) is substantial enough to be the report itself, not just an announcement of one.
2020-06-24 French
Eurobio Scientific déploie ses solutions de diagnostic du Coronavirus
Regulatory Filings Classification · 100% confidence The document is a press release dated March 3, 2020, announcing the commercialization of Coronavirus diagnostic tests (ALLPLEX™ and proprietary EBX Coronavirus test) and providing updates on regulatory progress (CE marking, CNR validation). It also mentions upcoming financial results ('Résultats annuels 2019 : 14 avril 2020'). This content structure—a timely announcement of business developments, product launches, and operational updates, often including forward-looking statements and contact information—is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it focuses on immediate business news rather than a comprehensive periodic financial report (like 10-K or IR), 'ER' (Earnings Release) is the most appropriate fit, as these releases often accompany or precede formal earnings announcements, even if the primary focus here is operational news related to the emerging health crisis. It is not a transcript (CT), a full annual report (10-K), or a proxy statement (DEF 14A). Given the context of providing key operational updates related to a major event, ER is selected over the general RNS.
2020-03-03 French
Eurobio Scientific : marquage CE du test Coronavirus de Seegene™
Regulatory Filings Classification · 100% confidence The document is a press release dated February 18, 2020, announcing that Eurobio Scientific has received CE marking for a COVID-19 diagnostic test developed by Seegene. It details a specific operational/product achievement (CE marking) and mentions upcoming financial dates (Annual Results 2019). This type of announcement, focusing on a specific business event, product approval, or partnership, is generally classified as a general Regulatory Filing (RNS) if it doesn't fit a more specific category like Earnings Release (ER) or Capital Update (CAP). Since it is not a full report (like 10-K or IR) and is not about management changes (MANG), dividends (DIV), or insider trading (DIRS), RNS is the most appropriate general regulatory announcement category. The document length is short (2787 chars), suggesting it is an announcement rather than a comprehensive report.
2020-02-18 French
Eurobio Scientific intègre les tests du Coronavirus dans sa gamme de biologie moléculaire
Regulatory Filings Classification · 99% confidence The document is a press release dated February 10, 2020, announcing that Eurobio Scientific is integrating Coronavirus tests into its molecular biology range, specifically mentioning a partnership with Seegene and the development of a proprietary kit. It also lists upcoming financial events ('Résultats annuels 2019 : 14 avril 2020'). This content structure—a news announcement about a business development, product update, or operational event, often including contact information and a brief company profile—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (like 10-K or IR) but an announcement of operational news, ER is the most appropriate fit, as these releases often contain key operational highlights preceding formal financial reports. It is not a transcript (CT), a management discussion (MDA), or a formal proxy/governance document.
2020-02-10 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.